19. Results for TFST (all risk groups combined, narratively reported).
| Trial | Definition of subsequent therapy | Participants | Intervention (N randomised) | n with subsequent anticancer treatment | Comparator (N randomised) | n with subsequent anticancer treatment |
| Comparisons including SUN (in no particular order) | ||||||
| NCT00098657/NCT00083889 | "any poststudy cancer treatment for patients who discontinued from the trial" | all risk groups (according to MSKCC) | SUN (N=375) | n=182 | IFN (N=375) | n=213 |
| NCT00619268 comparison 1 | "second‐line therapy after study treatment failure" | all risk groups (according to MSKCC) | TEM+BEV (N=88) | n=61 | SUN (N=42) | n=20 |
| NCT00619268 comparison 2 | "second‐line therapy after study treatment failure" | all risk groups (according to MSKCC) | IFN+BEV (N=41) | n=27 | SUN (N=42) | n=20 |
| NCT01108445 | "subsequent therapy after progression" | all risk groups (according to MSKCC) | EVE (N=57) | n=33 | SUN (N=51) | n=36 |
| NCT01835158 | "subsequent anticancer therapy" | intermediate and poor risk groups (according to IMDC) | CAB (N=79) | n=51 | SUN (N=72) | n=50 |
| NCT02231749 | "any subsequent therapy" | all risk groups (according to IMDC) | NIV+IPI (N=550) | n=330 | SUN (N=546) | n=382 |
| NCT01984242 comparison 1** | "subsequent therapy for patients who progressed" | all risk groups (according to MSKCC) | ATE (N=103) | n=62 | SUN (N=101) | n=79 |
| NCT02420821 | "subsequent systemic treatment" | all risk groups (according to MSKCC) | ATE+BEV (N=454) | n=193 | SUN (N=461) | n=238 |
| NCT02684006 | "subsequent anticancer therapy" | all risk groups (according to IMDC) | AVE+AXI (N=442) | n=138 | SUN (N=444) | n= 227 |
| NCT02853331 | "subsequent anticancer therapy" | all risk groups (according to IMDC) | PEM+AXI (N=432) | n=204 | SUN (N=429) | n=281 |
| NCT00732914 | "subseuqent therapy for patients who discontinued the study after first‐line therapy" (cross over trial) | all risk groups (according to MSKCC) | SOR (N=74)*** | n=13 | SUN (N=100)*** | n=24 |
| NCT01024920 | "post‐study anticancer therapy" | all risk groups (according to MSKCC) | NIN (N=64) | n=25 | SUN (N=32) | n=8 |
| NCT03141177 | "subsequent anticancer therapy" | all risk groups (according to IMDC) | NIV+CAB (N=323) | n=61 | SUN (N=328) | n=108 |
| NCT02811861 comparison 1 | "any subsequent therapy" | all risk groups (according to MSKCC and IMDC) | LEN+PEM (N=355) | n=117 | SUN (N=357) | n=206 |
| NCT02811861 comparison 2 | "any subsequent therapy" | all risk groups (according to MSKCC and IMDC) | LEN+EVE (N=357) | n=167 | SUN (N=357) | n=206 |
| Other comparisons (in no particular order) | ||||||
| NCT00081614 | "second‐line therapy" | favourable and intermediate risk groups (according to MSKCC) | BEV+ERL (N=51) | n=7 | BEV+PLA (N=53) | n=17 |
| NCT00738530 | "post‐protocol therapy (not limited to second‐line therapy) of patients progressive disease or those in whom trial therapy was discontinued" | all risk groups (according to MSKCC) | IFN+BEV (N=327) | n=180 | IFN+PLA (N=322) | n=202 |
| NCT00609401 | "subsequent therapy (second‐line) at relapse" | all risk groups (according to MSKCC) | SOR+ILN (N=66) | n=49 | SOR (N=62) | n=48 |
| NCT00619268 comparison 3* | "second‐line therapy after study treatment failure" | all risk groups (according to MSKCC) | TEM+BEV (N=88) | n=61 | IFN+BEV (N=41) | n=27 |
| NCT01274273 | "subsequent systemic anticancer therapy following study treatment discontinuation" | favourable and intermediate risk groups according to MSKCC; all risk groups according to IMDC | ILN+IFN+BEV (N=59) | n=50 | ILN+IFN (N=59) | n=46 |
| NCT00719264 | "new cancer therapy after treatment discontinuation" | all risk groups (according to MSKCC) | EVE+BEV (N=182) | n=3 | IFN+BEV (N=183) | n=2 |
| NCT00920816 | "follow‐up systemic therapy after discontinuation of study treatment" | all risk groups (according to MSKCC) | AXI (N=192) | n=29 | SOR (N=96) | n=19 |
| NCT02811861 comparison 3* | "any subsequent therapy" | all risk groups (according to MSKCC and IMDC) | LEN+PEM (N=355) | n=117 | LEN+EVE (N=357) | n=167 |
*In the three‐arm trials, only two comparisons (arm A versus arm C (comparison 1) and arm B versus arm C (comparsion 2)) were reported, so we manually added a third comparison (arm A versus arm B (comparison 3)).
**Three‐arm trial, only data for this comparison (arm A versus arm C) was reported.
***Cross over trial. N represents number of participants who received only first‐line (first‐period) treatment.